108 related articles for article (PubMed ID: 29373637)
1. No evidence for rare TRAP1 mutations influencing the risk of idiopathic Parkinson's disease.
Gaare JJ; Nido GS; Sztromwasser P; Knappskog PM; Dahl O; Lund-Johansen M; Alves G; Tysnes OB; Johansson S; Haugarvoll K; Tzoulis C
Brain; 2018 Mar; 141(3):e16. PubMed ID: 29373637
[No Abstract] [Full Text] [Related]
2. Reply: No evidence for rare TRAP1 mutations influencing the risk of idiopathic Parkinson's disease.
Fitzgerald JC; Zimprich A; Reddy Bobbili D; Sharma M; May P; Krüger R
Brain; 2018 Mar; 141(3):e17. PubMed ID: 29373630
[No Abstract] [Full Text] [Related]
3. Development of a mitochondria-targeted Hsp90 inhibitor based on the crystal structures of human TRAP1.
Lee C; Park HK; Jeong H; Lim J; Lee AJ; Cheon KY; Kim CS; Thomas AP; Bae B; Kim ND; Kim SH; Suh PG; Ryu JH; Kang BH
J Am Chem Soc; 2015 Apr; 137(13):4358-67. PubMed ID: 25785725
[TBL] [Abstract][Full Text] [Related]
4. Commentary: Metformin reverses TRAP1 mutation-associated alterations in mitochondrial function in Parkinson's disease.
Rai SN; Singh SS; Birla H; Zahra W; Rathore AS; Singh P; Singh SP
Front Aging Neurosci; 2018; 10():221. PubMed ID: 30108499
[No Abstract] [Full Text] [Related]
5. PINK1 protects against oxidative stress by phosphorylating mitochondrial chaperone TRAP1.
Pridgeon JW; Olzmann JA; Chin LS; Li L
PLoS Biol; 2007 Jul; 5(7):e172. PubMed ID: 17579517
[TBL] [Abstract][Full Text] [Related]
6. TRAP1: a viable therapeutic target for future cancer treatments?
Lettini G; Maddalena F; Sisinni L; Condelli V; Matassa DS; Costi MP; Simoni D; Esposito F; Landriscina M
Expert Opin Ther Targets; 2017 Aug; 21(8):805-815. PubMed ID: 28664757
[TBL] [Abstract][Full Text] [Related]
7. TRAP1 regulation of mitochondrial life or death decision in cancer cells and mitochondria-targeted TRAP1 inhibitors.
Kang BH
BMB Rep; 2012 Jan; 45(1):1-6. PubMed ID: 22281005
[TBL] [Abstract][Full Text] [Related]
8. Parkinson's disease: pro-survival effects of PINK1.
Abeliovich A
Nature; 2007 Aug; 448(7155):759-60. PubMed ID: 17700685
[No Abstract] [Full Text] [Related]
9. Protective role of heat shock proteins in Parkinson's disease.
Aridon P; Geraci F; Turturici G; D'Amelio M; Savettieri G; Sconzo G
Neurodegener Dis; 2011; 8(4):155-68. PubMed ID: 21212626
[TBL] [Abstract][Full Text] [Related]
10. Hsp90 inhibitors disrupt mitochondrial homeostasis in cancer cells.
Neckers L; Kern A; Tsutsumi S
Chem Biol; 2007 Nov; 14(11):1204-6. PubMed ID: 18022558
[TBL] [Abstract][Full Text] [Related]
11. Translocation of the Dictyostelium TRAP1 homologue to mitochondria induces a novel prestarvation response.
Morita T; Amagai A; Maeda Y
J Cell Sci; 2004 Nov; 117(Pt 24):5759-70. PubMed ID: 15507488
[TBL] [Abstract][Full Text] [Related]
12. Translational Shift of HSP90 as a Novel Therapeutic Target from Cancer to Neurodegenerative Disorders: An Emerging Trend in the Cure of Alzheimer's and Parkinson's Diseases.
Alam Q; Alam MZ; Sait KHW; Anfinan N; Noorwali AW; Kamal MA; Khan MSA; Haque A
Curr Drug Metab; 2017; 18(9):868-876. PubMed ID: 28758577
[TBL] [Abstract][Full Text] [Related]
13. Mitochondrial DNA in CSF distinguishes LRRK2 from idiopathic Parkinson's disease.
Podlesniy P; Vilas D; Taylor P; Shaw LM; Tolosa E; Trullas R
Neurobiol Dis; 2016 Oct; 94():10-7. PubMed ID: 27260835
[TBL] [Abstract][Full Text] [Related]
14. Mitochondrial chaperone Trap1 and the calcium binding protein Sorcin interact and protect cells against apoptosis induced by antiblastic agents.
Landriscina M; Laudiero G; Maddalena F; Amoroso MR; Piscazzi A; Cozzolino F; Monti M; Garbi C; Fersini A; Pucci P; Esposito F
Cancer Res; 2010 Aug; 70(16):6577-86. PubMed ID: 20647321
[TBL] [Abstract][Full Text] [Related]
15. The Structural Asymmetry of Mitochondrial Hsp90 (Trap1) Determines Fine Tuning of Functional Dynamics.
Moroni E; Agard DA; Colombo G
J Chem Theory Comput; 2018 Feb; 14(2):1033-1044. PubMed ID: 29320629
[TBL] [Abstract][Full Text] [Related]
16. Guardian of the furnace: mitochondria, TRAP1, ROS and stem cell maintenance.
Kadye R; Kramer AH; Joos-Vandewalle J; Parsons M; Njengele Z; Hoppe H; Prinsloo E
IUBMB Life; 2014 Jan; 66(1):42-5. PubMed ID: 24382805
[TBL] [Abstract][Full Text] [Related]
17. Changes in spatial and temporal localization of Dictyostelium homologues of TRAP1 and GRP94 revealed by immunoelectron microscopy.
Yamaguchi H; Morita T; Amagai A; Maeda Y
Exp Cell Res; 2005 Feb; 303(2):415-24. PubMed ID: 15652353
[TBL] [Abstract][Full Text] [Related]
18. New TRAP1 and Hsp90 chaperone inhibitors with cationic components: Preliminary studies on mitochondrial targeting.
Rondanin R; Lettini G; Oliva P; Baruchello R; Costantini C; Trapella C; Simoni D; Bernardi T; Sisinni L; Pietrafesa M; Ponterini G; Costi MP; Vignudelli T; Luciani R; Matassa DS; Esposito F; Landriscina M
Bioorg Med Chem Lett; 2018 Jul; 28(13):2289-2293. PubMed ID: 29807796
[TBL] [Abstract][Full Text] [Related]
19. Advances in GBA-associated Parkinson's disease--Pathology, presentation and therapies.
Barkhuizen M; Anderson DG; Grobler AF
Neurochem Int; 2016 Feb; 93():6-25. PubMed ID: 26743617
[TBL] [Abstract][Full Text] [Related]
20. Rotenone Susceptibility Phenotype in Olfactory Derived Patient Cells as a Model of Idiopathic Parkinson's Disease.
Murtaza M; Shan J; Matigian N; Todorovic M; Cook AL; Ravishankar S; Dong LF; Neuzil J; Silburn P; Mackay-Sim A; Mellick GD; Wood SA
PLoS One; 2016; 11(4):e0154544. PubMed ID: 27123847
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
